Mediolanum International Funds Ltd grew its position in ResMed Inc. (NYSE:RMD – Free Report) by 3.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,130 shares of the medical equipment provider’s stock after purchasing an additional 4,735 shares during the period. Mediolanum International Funds Ltd owned about 0.09% of ResMed worth $27,532,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in RMD. Hsbc Holdings PLC grew its stake in ResMed by 17.6% in the 4th quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider’s stock valued at $79,321,000 after purchasing an additional 49,253 shares during the period. Nordea Investment Management AB increased its position in shares of ResMed by 37.2% during the 4th quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock valued at $262,027,000 after purchasing an additional 294,124 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of ResMed by 13.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider’s stock worth $235,833,000 after purchasing an additional 118,296 shares during the period. Fideuram Asset Management Ireland dac bought a new stake in shares of ResMed during the 4th quarter worth $4,712,000. Finally, Regatta Capital Group LLC purchased a new position in shares of ResMed in the 4th quarter worth about $2,508,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at ResMed
In other news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the transaction, the chief executive officer owned 466,223 shares in the company, valued at $101,893,036.65. This trade represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 14,973 shares of company stock valued at $3,096,067 in the last three months. 0.65% of the stock is owned by company insiders.
Analyst Ratings Changes
Get Our Latest Stock Report on RMD
ResMed Stock Down 1.9%
Shares of NYSE RMD opened at $198.86 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The stock has a market capitalization of $28.85 billion, a PE ratio of 19.18, a P/E/G ratio of 1.19 and a beta of 0.78. ResMed Inc. has a one year low of $180.26 and a one year high of $293.81. The business’s fifty day moving average price is $199.40 and its 200-day moving average price is $226.64.
ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.42 billion. During the same quarter last year, the firm posted $2.37 EPS. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, equities research analysts anticipate that ResMed Inc. will post 11.13 EPS for the current year.
ResMed Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Thursday, May 14th. ResMed’s dividend payout ratio (DPR) is currently 23.14%.
ResMed Company Profile
ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.
ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.
Featured Articles
- Five stocks we like better than ResMed
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD – Free Report).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
